Scarica l'app Stockscreener
206.10
0.90%
-1.88
Dopo l'orario di chiusura:
206.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$207.98
Aprire:
$209.07
Volume 24 ore:
1.31M
Relative Volume:
1.12
Capitalizzazione di mercato:
$29.90B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
19.87
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
-1.79%
1M Prestazione:
-7.17%
6M Prestazione:
-19.19%
1 anno Prestazione:
-16.29%
Intervallo 1D:
$206.06
$211.56
Intervallo di 1 settimana:
$205.65
$211.56
Portata 52W:
$198.61
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
206.10 | 30.17B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
418.55 | 154.64B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.24 | 40.71B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.35 | 33.02B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.84 | 30.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Form 144: RMD (NYSE) affiliate lists 8,000 shares; insider sold 2,000 - Stock Titan
Jefferies Financial Group Inc. Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Tandem Investment Advisors Inc. Cuts Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock (US7611521078): sleep-apnea specialist in focus after latest earnings update - AD HOC NEWS
ResMed Stock Near 52-Week Low Despite 21% EPS Growth: Here’s What the GLP-1 Data Actually Shows - TIKR.com
Do Wall Street Analysts Like ResMed Stock? - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Robust Growth Potential Amidst Healthcare Innovations - DirectorsTalk Interviews
Life Cycle Investment Partners Ltd Invests $31.23 Million in ResMed Inc. $RMD - MarketBeat
Catalyst Funds Management Pty Ltd Sells 8,400 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cumberland Partners Ltd Purchases 8,000 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed Sleep Tech Push Is Turning Heads? - Kalkine Media
EMA backs first oral Wegovy weight-loss pill for EU - MSN
Thrivent Financial for Lutherans Buys 11,481 Shares of ResMed Inc. $RMD - MarketBeat
Is the options market predicting a spike in ResMed stock? - MSN
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed Inc stock (US75102W1036): sleep apnea specialist draws attention after latest options moves - AD HOC NEWS
How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem - Sahm
ResMed stock (US7611521078): sleep apnea specialist in focus after latest earnings - AD HOC NEWS
How Investors Are Reacting To ResMed (RMD) Linking Oura Ring Wearables To Clinical Sleep Care - Yahoo Finance
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Is the Options Market Predicting a Spike in ResMed Stock? - Zacks Investment Research
ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results - AD HOC NEWS
ResMed (RMD) Valuation Check As Oura Sleep Health Collaboration Aims To Expand Sleep Apnea Care Access - Yahoo Finance
5,006 Shares in ResMed Inc. $RMD Acquired by North Dakota State Investment Board - MarketBeat
Resmed, Oura partner on sleep health education, care - MassDevice
Resmed (RMD) Teams Up with Oura to Enhance Sleep Health Educatio - GuruFocus
ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways - Moomoo
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference - Caledonian Record
ResMed Targets Circadian Data With New Wearable Trial: What Investors Should Watch - TipRanks
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care - marketscreener.com
Oura Ring now links sleep changes to Resmed sleep resources - Stock Titan
ResMed Inc stock (US75102W1036): sleep apnea specialist in focus after fresh institutional buying - AD HOC NEWS
ResMed Inc. stock (US7611521078): Earnings beat and dividend lift focus - AD HOC NEWS
Watchman Group, Inc.'s ResMed Inc(RMD) Holding History - GuruFocus
Why this fallen ASX 200 blue chip could be a strong buy - MSN
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Should you continue to hold Resmed stock in your portfolio? - MSN
Integrated Investment Consultants LLC Invests $1.34 Million in ResMed Inc. $RMD - MarketBeat
Passumpsic Savings Bank Purchases New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Exploring a 34% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed Inc. stock (US7611521078): dividend in focus after solid Q3 results - AD HOC NEWS
Why are ResMed shares lagging if the business keeps compounding? - MSN
Stephens Investment Management Group LLC Decreases Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MSN
With Strong Cash Flow, ResMed Stock Poised to Rise? - Trefis
Strong Cash Yield: Is ResMed Stock A Buy? - Trefis
ResMed Inc stock (US75102W1036): Noctrix deal, dividend and shifting sentiment put sleep-therapy spe - AD HOC NEWS
Arbejdsmarkedets Tillaegspension Makes New Investment in ResMed Inc. $RMD - MarketBeat
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):